



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

HL

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/109,864 07/06/98 NI

J PF354P1

022195
HUMAN GENOME SCIENCES INC
9410 KEY WEST AVENUE
ROCKVILLE MD 20850

HM22/0218

EXAMINER

ULM, J

ART UNIT

PAPER NUMBER

1646

DATE MAILED:

02/18/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.
09/109,864

Applicant(s)
Ni et al.

Examiner
John Ulm

Group Art Unit
1646



☒ Responsive to communication(s) filed on Dec 7, 1999

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

☒ Claim(s) 29-105 is/are pending in the application.

Of the above, claim(s) _____ is/are withdrawn from consideration.

☐ Claim(s) _____ is/are allowed.

☒ Claim(s) 29-105 is/are rejected.

☐ Claim(s) _____ is/are objected to.

☐ Claims _____ are subject to restriction or election requirement.

Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on _____ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
☐ received.

☐ received in Application No. (Series Code/Serial Number) _____

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

☒ Notice of References Cited, PTO-892

☒ Information Disclosure Statement(s), PTO-1449, Paper No(s). 9

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1646

1) Claims 29 to 105 are pending in the instant application. Claims 1 to 28 have been canceled and claims 29 to 105 have been added as requested by Applicant in Paper Number 8, filed 07 December of 1999.

2) Applicant's traversal of the restriction requirement of Paper Number 4 is moot because Applicant has canceled all claims to any nonelected inventions. The traversal is on the grounds that a search of the different inventions in a single application would pose no undue burden. This is not found persuasive because M.P.E.P. 803 states that:

“ For purposes of the initial requirement, a serious burden on the examiner may be prima facie shown if the examiner shows by appropriate explanation either separate classification, separate status in the art, or a different field of search as defined in MPEP § 808.02. That prima facie showing may be rebutted by appropriate showings or evidence by the applicant.”

Serious burden was shown in the original requirement by the separate classification and separate status in the art of the different inventions. Applicant has provided neither a showing or evidence to the contrary. The requirement is still deemed proper and is therefore made FINAL.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3) Claims 96 to 105 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had

Art Unit: 1646

possession of the claimed invention. There is absolutely no written description in the instant specification of an isolated nucleic acid encoding an allelic variant or a species homologue of a protein comprising the amino acid sequence presented in SEQ ID NO:2 of the instant application.

In the decision of *The Regents of the University of California v. Eli Lilly and Company*, 43 USPQ2d 1398 (CAFC 1997), the court held that:

"To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that 'the inventor invented the claimed invention.' *Lockwood v. American Airlines, Inc.*, 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); *In re Gosteli*, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) ('[T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed.'). Thus, an applicant complies with the written description requirement 'by describing the invention, with all its claimed limitations, not that which makes it obvious,' and by using 'such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention.' *Lockwood*, 107 F.3d at 1572, 41 USPQ2d at 1966.

An adequate written description of a DNA, such as the cDNA of the recombinant plasmids and microorganisms of the '525 patent, 'requires a precise definition, such as by structure, formula, chemical name, or physical properties,' not a mere wish or plan for obtaining the claimed chemical invention. *Fiers v. Revel*, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, 'an adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself.' *Id.* at 1170, 25 USPQ2d at 1606.

Art Unit: 1646

Whereas the instant specification provides a detailed description of a single isolated DNA encoding particular protein having very specific physical and structural properties, the instant specification does not provide a structural formula which is definitive of all, or even one allelic variant or species homologue of that one protein. The instant specification also fails to provide "a precise definition, such as by structure, formula, chemical name, or physical properties," of the genus of isolated nucleic acids encompassed by these claims.

4) Claims 29, 32 to 43 and 86 to 95 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. These claims expressly require deposited material recited therein.

Applicant, their assignee or their agent needs to provide a declaration containing the following:

The identification of the declarant.

A statement that a deposit has been made in a depository affording permanence of the deposit and ready accessibility thereto by the public if a patent is granted. The depository is to be identified by name and address.

A statement that the deposited material has been accorded a specific, recited, accession number.

A statement that the material has been deposited under conditions that assure that access to the material will be available during the pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. 1.14 and 35 U.S.C. § 122.

Art Unit: 1646

A statement that the deposited material will be maintained with all of the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposited microorganism, and in any case, for a period of at least thirty years after the date of deposit or for the enforceable life of the patent, whichever period is longer.

A statement by declarant that all statement made therein of declarant's knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant patent application or any patent issuing thereon.

Alternately, it may be averred that deposited material has been accepted for deposit under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (e.g., see 961 OG 21, 1977) and that all restrictions on the availability to the public of the material so deposited will be irrevocably removed upon the granting of a patent. Additionally, the deposit must be referred to in the body of the specification and be identified by deposit (accession number) number, name and address of the depository, and the complete taxonomic description.

5) Claims 42, 73, 84, 94 and 104 are rejected under 35 U.S.C. 112, first paragraph, as based on a disclosure which is not enabling. An invention which requires elements that are critical or essential to the practice of the invention, but not included in the claim(s) is not enabled by the disclosure. See *In re Mayhew*, 527 F.2d 1229, 188 USPQ 356 (CCPA 1976). These claims are drawn to a process of producing a protein but the claims are not limited to a process which employs a nucleic acid that encodes the protein produced by the claimed process. Claim

Art Unit: 1646

42, for example, is drawn to a process of producing "a polypeptide encoded by the nucleic acid molecule of claim 29", whereas claim 29 is not limited to a nucleic acid molecule encoding a protein.

Whereas the instant claims encompass a process of making a plurality of different proteins, the instant specification does not disclose how to make and use a protein comprising other than all or a specific portion of the amino acid sequence presented in SEQ ID NO:2 of the instant application. The instant claims encompass a process of producing a very broad genus of proteins from which the instant application discloses only one member of that genus. *In re Clarke*, 148 USPQ 665, (CCPA 1966) held that;

" It appears to be well settled that a single species can rarely, if ever, afford support for a generic claim. *In re Soll*, 25 C.C.P.A. (Patents) 1309, 97 F.2d 623, 38 USPQ 189; *In re Wahlforss et al.*, 28 C.C.P.A. (Patents) 867, 117 F.2d 270, 48 USPQ 397. The decisions do not however fix any definite number of species which will establish completion of a generic invention and it seems evident therefrom that such number will vary, depending on the circumstances of particular cases. Thus, in the case of a small genus such as halogens, consisting of four species, a reduction to practice of three, or perhaps even two, might serve to complete the generic invention, while in the case of a genus comprising hundreds of species, a considerably large number of reductions to practice would probably be necessary."

Because the instant application does not identify the amino acid residues in SEQ ID NO:2 that are essential for the functional and structural integrity of that protein and those residues which are expendable or substitutable, it is not enabling for the present scope of these claims. Because the

Art Unit: 1646

instant specification does not identify a structurally and functionally analogous protein for which this information is known and could be applied to a protein of the instant invention by analogy, an artisan can not look to the prior art for the needed guidance. Whereas the claims encompass a process of producing of intentionally altered proteins, the instant specification does not provide a working example of a process of making even one protein with an intentionally modified amino acid sequence. *In re Fisher*, 427 F.2d 833, 166 USPQ 18 (CCPA 1970), held that

"Inventor should be allowed to dominate future patentable inventions of others where those inventions were based in some way on his teachings, since such improvements while unobvious from his teachings, are still within his contribution, since improvement was made possible by his work; however, he must not be permitted to achieve this dominance by claims which are insufficiently supported and, hence, not in compliance with first paragraph of 35 U.S.C. 112; that paragraph requires that scope of claims must bear a reasonable correlation to scope of enablement provided by specification to persons of ordinary skill in the art; in cases involving predictable factors, such as mechanical or electrical elements, a single embodiment provides broad enablement in the sense that, once imagined, other embodiments can be made without difficulty and their performance characteristics predicted by resort to known scientific law; in cases involving unpredictable factors, such as most chemical reactions and physiological activity, scope of enablement varies inversely with degree of unpredictability of factors involved."

Because the instant specification does not provide the essential structural and functional information about SEQ ID NO:2, an artisan can not produce a protein which has been altered at even a single amino acid residue and predict, "by resort to known scientific law", if that modified protein will produce an authentic response.

Art Unit: 1646

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6) Claims 42, 73, 84, 94 and 104 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. These claims are vague and indefinite because there is no clear antecedent basis for "a polypeptide encoded by the nucleic acid of claim" since the claims from which they depend are not required to encode a polypeptide.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7) Claims 29, 35, 36, 38, 40, 44 to 67, 69, 71, 75 to 78, 80, 82, 86 to 88, 90, 92, 96 to 98, 100 and 102 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by the Adams et al. publication (NATURE 377:3-17, 28 Sep. 1995, EST181872, GenBank Accession Number AA311108). The nucleotide sequence of bases 54 to 452 of the cDNA identified in Venter et al. as EST181872 is identical to the coding region of SEQ ID NO:1 in all but one base. That cDNA was cloned into a lambda vector, which encodes a plurality of "heterologous" proteins, and propagated in an *Escherichia coli* host cell.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1646

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

8) Claims 43, 85, 95 and 105 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over the Adams et al. publication cited above. These claims differ from claims 29, 35, 36, 38, 40, 44 to 67, 69, 71, 75 to 78, 80, 82, 86 to 88, 90, 92, 96 to 98, 100 and 102 above in requiring the claim nucleic acid to be contained in a pharmacologically acceptable carrier. The PCR buffer that was described in the last paragraph on page 4 of Venter et al. appears to be a pharmacologically acceptable carrier. If not, it would have been prima facie to one of ordinary skill in the art of molecular biology to have incorporated a cDNA of Venter et al. into a pharmacologically acceptable carrier to facilitate its manipulation by those techniques that were routine in the art at that time.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

Art Unit: 1646

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kuntz can be reached at (703) 308-4623.

Official papers filed by fax should be directed to (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.



JOHN ULM
PRIMARY EXAMINER
GROUP 1600